Celyad Oncology SA (CYAD) Financials

NASDAQ Currency in USD Disclaimer

$0.47

north_east NA Past Year
Day's range
$0.47
Day's range
$0.53

CYAD Income statement / Annual

Last year (2023), Celyad Oncology SA's total revenue was $102,000.00, and the percentage change from the previous year is not available. In 2023, Celyad Oncology SA's net income was -$8.45 M. See Celyad Oncology SA,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $102,000.00 $0.00 $0.00 $5,000.00 $6,000.00 $3.12 M $3.54 M $8.52 M $3,000.00 $146,000.00
Cost of Revenue $69,000.00 $1.44 M $1.52 M $0.00 $0.00 $0.00 $515,000.00 $53,000.00 $6.38 M $115,000.00
Gross Profit $33,000.00 -$1.44 M -$1.52 M $5,000.00 $6,000.00 $3.12 M $3.03 M $8.47 M -$6.38 M $31,000.00
Gross Profit Ratio 0.32 0 0 1 1 1 0.85 0.99 -2126.33 0.21
Research and Development Expenses $4.67 M $18.93 M $20.77 M $21.59 M $25.23 M $23.58 M $22.91 M $27.68 M $5.90 M $15.87 M
General & Administrative Expenses $5.71 M $10.34 M $9.67 M $9.00 M $8.73 M $10.39 M $9.31 M $9.74 M $7.23 M $5.02 M
Selling & Marketing Expenses $215,000.00 $239,000.00 $434,000.00 $454,000.00 $607,000.00 $676,000.00 $761,000.00 $728,000.00 $891,000.00 $394,000.00
Selling, General & Administrative Expenses $6.25 M $10.34 M $9.67 M $9.00 M $8.73 M $10.39 M $9.31 M $9.74 M $7.23 M $5.02 M
Other Expenses -$2.43 M -$9.00 M -$3.53 M -$4.34 M -$4.58 M $7.32 M -$23.79 M -$2.52 M -$222,000.00 -$963,000.00
Operating Expenses $8.49 M $20.26 M $26.91 M $26.24 M $29.38 M $41.29 M $29.63 M $34.08 M $29.68 M $19.92 M
Cost And Expenses $8.56 M $20.26 M $26.91 M $26.24 M $29.38 M $41.29 M $30.14 M $34.13 M $29.68 M $20.03 M
Interest Income $30,000.00 $12,000.00 $27,000.00 $51,000.00 $92,000.00 $804,000.00 $933,000.00 $2.20 M $542,000.00 $277,000.00
Interest Expense $84,000.00 $197,000.00 $255,000.00 $297,000.00 $343,000.00 $62,000.00 $4.45 M $207,000.00 $236,000.00 $22,000.00
Depreciation & Amortization $794,000.00 $1.44 M $1.52 M $1.83 M $1.79 M $1.11 M $1.71 M $1.52 M $1.03 M $870,000.00
EBITDA -$7.76 M -$39.70 M -$25.41 M -$15.73 M -$27.45 M -$36.56 M -$55.70 M -$21.99 M -$28.07 M -$15.32 M
EBITDA Ratio -76.11 0 0 -4838.4 -4575 -12 -4.71 -2.57 -9281.67 -123.59
Operating Income Ratio -82.91 0 0 -5247.8 -4895.5 -12.25 -14.94 -3 -9890.67 -112.58
Total Other Income/Expenses Net -$54,000.00 -$13,000.00 -$111,000.00 -$217,000.00 $239,000.00 $433,000.00 -$3.52 M $2.00 M $558,000.00 -$16,000.00
Income Before Tax -$8.51 M -$40.87 M -$26.50 M -$17.20 M -$28.64 M -$37.43 M -$56.40 M -$23.61 M -$29.11 M -$16.45 M
Income Before Tax Ratio -83.44 0 0 -3440.8 -4773.33 -12.02 -15.93 -2.77 -9704.67 -112.69
Income Tax Expense -$191,000.00 $65,000.00 $10,000.00 $297,000.00 -$8,000.00 -$1.11 M -$1,000.00 -$6,000.00 -$55,000.00 -$2.48 M
Net Income -$8.45 M -$40.94 M -$26.51 M -$17.50 M -$28.63 M -$36.31 M -$56.40 M -$23.61 M -$29.11 M -$16.45 M
Net Income Ratio -82.82 0 0 -3500.2 -4772 -11.66 -15.93 -2.77 -9704.67 -112.69
EPS -0.33 -1.81 -1.7 -1.26 -2.29 -3.26 -5.86 -2.53 -3.43 -2.44
EPS Diluted -0.33 -1.81 -1.7 -1.26 -2.29 -3.26 -5.86 -2.53 -3.43 -2.44
Weighted Average Shares Out $25.72 M $22.59 M $15.60 M $13.94 M $12.52 M $11.14 M $9.62 M $9.31 M $8.48 M $6.75 M
Weighted Average Shares Out Diluted $25.72 M $22.59 M $15.60 M $13.94 M $12.52 M $11.14 M $9.62 M $9.33 M $8.49 M $6.75 M
Link